Loading organizations...
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 9, 2026 | Diagonal Therapeutics | $125.0M Series B | Janus Henderson Investors, Paulina Hill | Atlas Venture, Balyasny Asset Management, Biovision Ventures, BVF Partners, Deep Track Capital, EcoR1 Capital, Frazier Life Sciences, Lightspeed Venture Partners, Logos Capital, RA Capital Management, RV Invest, Velosity Capital, Viking Global Investors |
| Apr 1, 2024 | Diagonal Therapeutics | $130.0M Series A | Atlas Venture, BVF Partners | Alta Partners, Double Prime LLP, Frazier Healthcare Partners, Pareto Holdings, Passion Capital, V3 Ventures, Mik Attisani, Oscar Pierre, Tom Blomfield, Frazier Life Sciences, Lightspeed Venture Partners, RA Capital Management, Velosity Capital, Viking Global Investors |